Table 2. Summary of Clinical Findings.
The first column lists the patient, age (years) at which the fluocinolone acetonide implanatation was first performed. The “preop” column contains data from the month prior to implantation. (Preop, preoperative; OD, right eye; OS, left eye; Logmar, logarithm of the minimal angle of resolution; VA, visual acuity; M, male; F, female; OCT, optical coherence tomography; Vit cells, vitreous cells; n/a, not available; HM, Hand motion; VH, vitreous hemorrhage).
| Patient | Eye | Exam | Preop | 6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 | 54 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1 (24-M) |
OD | Logmar VA Snellen VA |
0.70; 20/100 |
1.10; 20/250 |
0.90*; 20/160 |
0.70; 20/100 |
0.54; 20/70 |
0.70; 20/100 |
0.60; 20/80 |
0.70; 20/100 |
0.70; 20/100 |
0.60; 20/80 |
| OCT† | 663 (469) |
718 (524) |
323 (129) |
460 (207) |
323 (53) |
n/a | n/a | n/a | n/a | n/a | ||
| Vit cells | 2+ | trace | 0 | 0 | trace | 0 | trace | 0 | 0 | 0 | ||
| OS | Logmar VA Snellen VA |
0.48; 20/60 |
0.48; 20/60 |
0.48; 20/60 |
0.48‡; 20/60 |
0.80; 20/125 |
1.10; 20/250 |
1.00; 20/200 |
||||
| OCT | n/a | 431 (237) |
411 (217) |
485 (291) |
n/a | n/a | n/a | |||||
| Vit cells | 1+ | 0 | 0 | 0 | 0 | 0 | 0 | |||||
|
2 (44-F) |
OD | Logmar VA Snellen VA |
0.30; 20/40 |
0.40; 20/50 |
0.40; 20/50 |
0.40^; 20/50 |
0.40; 20/50 |
0.40; 20/50 |
0.48; 20/60 |
0.48; 20/60 |
0.40; 20/50 |
0.48; 20/60 |
| OCT | 393 (199) |
230 (36) |
256 (62) |
312 (59) |
313 (43) |
285 (15) |
n/a | n/a | n/a | n/a | ||
| Vit cells | 1+ | 0 | 0 | 0 | 0 | 0 | Trace | 0 | 0 | 0 | ||
| OS | Logmar VA Snellen VA |
1.10; 20/250 |
1.10; 20/250 |
0.70^; 20/100 |
1.10; 20/250 |
1.00; 20/200 |
0.90; 20/160 |
1.00; 20/200 |
||||
| OCT | 624 (430) |
227 (33) |
276 (82) |
369 (175) |
403 (209) |
414 (161) |
404 (134) |
|||||
| Vit Cells | 2+ | 0 | 0 | 0 | 0 | 0 | 0 | |||||
|
3 (36-F) |
OD | Logmar VA Snellen VA |
1.20; 20/320 |
0.60; 20/80 |
1.00; 20/200 |
1.10**; 20/250 |
1.30**; 20/400 |
1.10**; 20/250 |
||||
| OCT | 542 (348) |
325 (55) |
443 (173) |
486 (216) |
431 (161) |
434 (164) |
||||||
| Vit cells | 2+ | trace | 0 | 0 | trace | 1+ | ||||||
| OS | Logmar VA Snellen VA |
0.90; 20/160 |
0.90; 20/160 |
1.00; 20/200 |
1.00; 20/200 |
1.30; 20/400 |
||||||
| OCT | 296 (26) |
299 (29) |
304 (34) |
309 (39) |
318 (48) |
|||||||
| Vit cells | 1+ | 0 | 0 | 0 | 0 | |||||||
|
4 (38-F) |
OD | Logmar VA Snellen VA |
0.40; 20/50 |
0.48; 20/60 |
0.70; 20/100 |
n/a | 1.10; 20/250 |
|||||
| OCT | 306 (36) |
346 (76) |
302 (32) |
n/a | n/a | |||||||
| Vit cells | 3+ | trace | 0 | n/a | 0 | |||||||
| OS | VA Logmar VA Snellen VA |
0.30; 20/40 |
0.30; 20/40 |
0.48; 20/60 |
0.54; 20/60 |
0.48; 20/70 |
||||||
| OCT | 323 (129) |
n/a | n/a | 426 (156) |
320 (50) |
|||||||
| Vit cells | 2+ | 0 | 0 | 0 | 0 | |||||||
|
5 (53-F) |
OS | Logmar VA Snellen VA |
3.00; HM |
3.00; HM |
||||||||
| OCT | n/a | n/a | ||||||||||
| Vit cells | Dense VH |
0 |
Uncomplicated cataract surgery was performed during the preceding interval, as well as intravitreal injections of bevacizumab and triamcinolone acetonide
Data is presented first in microns, then in (microns greater than normative published mean for the imaging equipment and software utilized)
intravitreal bevacizumab administered during preceding interval
uncomplicated cataract surgery performed during preceding interval
uncomplicated cataract surgery performed with (OD) and without (OS) intravitreal injection of triamcinolone acetonide during preceding interval